Hospital 401 of Chinese PLA

Qingdao, China

Hospital 401 of Chinese PLA

Qingdao, China
SEARCH FILTERS
Time filter
Source Type

Wang L.,Hospital 401 of Chinese PLA | Wang L.,Qingdao University | Li M.-C.,Hospital 401 of Chinese PLA
Chinese Journal of Pharmacology and Toxicology | Year: 2015

Epidermal growth factor receptor-tyrosine kinase inhibitors(EGFR-TKI), such as gefitinib and erlotinib, were widely used in the treatment of non-small cell lung cancer (NSCLC). However, with the continuous application of EGFR-TKI, the sensitivity to tumor cells and the efficacy were reduced and drug resistance increased. Recently, much progress has been made in combining EGFR-TKI with other drugs. This paper summarizes the efficacy and molecular mechanism of EGFR-TKI combined with chemotherapeutic drugs, insulin-like growth factor 1 receptor TKI, antivascular endothelial growth factor monoclonal antibody, mammalian target of sirolimus(Rapamycin) inhibitor, cyclooxygenase-2 inhibitor, cytokine induced killer cell therapy and other drugs in order to facilitate clinical treatment of NSCLC.

Loading Hospital 401 of Chinese PLA collaborators
Loading Hospital 401 of Chinese PLA collaborators